Kisqali

Kisqali (ribociclib) is a prescription medication used to treat HR-positive, HER2-negative breast cancer. An oral targeted therapy for common types of advanced or early breast cancer, used together with hormone therapy.

Blocks CDK4/6 proteins that cancer cells use to divide, slowing tumor growth.

Commonly reported side effects of Kisqali include Low white blood cells, Nausea, Fatigue, Heart rhythm changes (QT), and Liver enzyme changes. This is not a complete list — tell your doctor or pharmacist about any side effects you experience.

Kisqali has notable warnings and precautions. Tell your doctor about your medical history and any other medicines or supplements you take before starting Kisqali.

The active ingredient in Kisqali is ribociclib, which belongs to a class of medicines known as CDK4/6 Inhibitor.

Kisqali is manufactured by Novartis. It was first approved in 2017.

You may be able to lower the cost of Kisqali by using a free pharmacy discount card or by comparing prices across pharmacies before you fill your prescription. Savings vary by pharmacy and location.